he transfection efficacy of several vectors containing the full genomic hAAT gene with its natural promoter (pTG7101) and others containing the cDNA of hAAT gene driven by cytomegalovirus immediate-early promoter or the 0.5 kb upstream of hAAT gene sequence has been studied by hydrodynamic tail-vein injection (20 mg/mouse). pTG7101 (but not the other plasmids) results in therapeutic and stable concentration of hAAT in plasma. A dose-response study with this plasmid (0.3-320 mg/mouse) confirms that hAAT remains long-term stable in plasma, with therapeutic concentrations of hAAT (40.9 mg/ml). The parameters of the dose-response curve were: R: 0.98, E max 3449.07 279.7 mg/ml and EC 50 1.2 Â 10 12 plasmid-gene units. In addition, 4 months after transfection, the intrinsic efficacy of transgenic expression (amount of RNA/DNA) in mouse liver was 50-80% that normally expressed by the mouse gene. The important efficacy of nonviral genomic DNA opens a new avenue in the safety applications of human gene therapy.
Introduction
Alpha-1-antitrypsin (AAT) is the most abundant serine protease inhibitor (serpin) in human plasma. It is a 52 kDa glycoprotein predominantly synthesized in hepatocytes and secreted into the bloodstream, protecting lung elastin from degradation by neutrophil elastase. Plasma levels of o0.8 mg/ml 1, 2 are associated with increased risks of early-onset pulmonary emphysema. Since human AAT deficiency may be a good candidate for clinical and experimental gene therapy strategies, a broad variety of systems have been developed to transfer genes into the liver, resulting in detectable serum levels of hAAT in animal models. [3] [4] [5] [6] [7] [8] Adenoviral vectors, 9,10 and more recently recombinant adeno-associated viral vectors, 11 have shown the ability to mediate therapeutic serum concentrations of hAAT. However, their usefulness in gene therapy could be limited by the pathogenic risks involved. [12] [13] [14] Safety concerns regarding these viruses have led to many efforts to develop other gene delivery systems. Recently, it has been demonstrated 15, 16 that naked DNA can be efficiently transfected into the liver via a rapid i.v. injection of plasmid in a large volume solution (the so-called hydrodynamic procedure). Based on this procedure, therapeutic but very transient 17 or stable but subtherapeutic 18 plasma levels of hAAT have been achieved in mice. In the present work, we study the gene transfer efficiency of several hAAT gene constructs employing the hydrodynamic procedure in mice, showing that it is possible to achieve therapeutic and longterm gene expression (44 months) of hAAT plasma levels, employing a plasmid (pTG7101) containing the full length of genomic hAAT gene driven by the natural promoter. The dose-response analysis of the amount of hAAT protein in plasma as a function of the amount of plasmid-gene molecules injected yields a good doseresponse curve (R¼0.98), from which the parameters E max (3449.07279.7 mg/ml) and EC 50 (1.2 Â 10 12 plasmidgene units) can be obtained. Additional experiments employing multiple doses confirm the existence of a maximal effect for hydrodynamic transfection. The goodness of the gene expression cassette was evaluated as the RNA/DNA ratio (gene intrinsic efficacy) of quantitative RT-PCR and PCR products of human and mouse AAT gene from livers of transfected mice.
Results

Gene transfer efficacy of different hAAT gene constructs
Experiments were performed to study the in vivo gene transfer efficacy of different gene constructs (Figure 1 ) measuring the protein level in plasma after hydrodynamic transfection. Accordingly, 20 mg of DNA was hydrodynamically injected into the tail vein of mice, consisting of plasmids containing the full genomic hAAT gene with its natural promoter (pTG7101), along with others containing the cDNA of hAAT gene driven by the CMV promoter (MOLK1) or a CMV promoter containing an intronic sequence (MOLK2) and the 0.5 kb upstream of the hAAT gene (pAK1). A study was also made of the efficacy of minigenes derived from corresponding plasmids containing cDNA gene constructs (K1, K2 and AK1, respectively) in which the gene region was cut, purified and the ends closed with specific hairpins. The in vivo transfection efficacy of each plasmid was assessed by measuring hAAT in plasma samples by ELISA, collected at appropriate time points. The most interesting observation (Figure 2a ) is that transfection with the plasmid containing the genomic DNA (pTG7101) results in therapeutic and stable levels of hAAT in plasma. Also, therapeutic values were observed using plasmid MOLK1 and the corresponding minigene K1, although this effect was limited to the first days after transfection. The plasmid MOLK2 also mediated the maximal effect in the first days, although at subtherapeutic levels. The corresponding minimalistic K2 showed lesser efficacy. The lowest gene expression efficacy was observed employing the plasmid pAK1 and the corresponding minigene AK1. On the other hand, the quantitative RT-PCR analysis of samples derived from total liver removed 1 month after transfection (Figure 2b ) confirms the previous data obtained by ELISA and shows the order of plasmid efficacy to be pTG71014pMOLK14 pMOLK24K14K24pAK14AK1.
Dose dependence of pTG7101
Groups of three animals were treated with a single hydrodynamic injection of pTG7101 (from 0.3 to 320 mg). The plasma levels of hAAT in mice were measured at different intervals during 4 months. In all cases, the results ( Figure 3 ) confirm that plasma levels of hAAT progressively increased to peak 2 weeks after transfection and then decreased very slowly over the next 4 months. Therapeutic levels of hAAT in plasma (1366, 2764 and 3252 mg/ml) were observed 15 days after transfection with 20, 40 and 80 mg pTG7101 plasmid, respectively. After 4 months, subtherapeutic values were recorded (410 mg/ml) in mice belonging to the group treated with 20 mg of plasmid. However, long-term therapeutic levels of hAAT protein were observed after hydrodynamic injection of 40 and 80 mg of pTG7101 plasmid, since levels of 945 and 1837 mg/ml, respectively, were observed 4 months after transfection.
The amount of hAAT protein in plasma (observed 2 weeks after transfection) as a function of the plasmidgene molecules injected results (Figure 4 ) in a good dose-response curve (R¼0.98) with an E max of 3449.07279.7 mg/ml and an EC 50 of 1.2 Â 10 12 plasmidic gene units. In our experiments, E max was achieved with 80 mg of pTG7101 plasmid. Additional experiments, employing multiple doses ( Figure 5 ), confirm the existence of a maximal effect for hydrodynamic transfection. In these experiments, two mice were injected with 20 mg of pTG7101 plasmid in 2 ml of saline, although in one group injection was performed in 5 s and in the other in 15 s, resulting (1 month after transfection) in hAAT protein plasma levels of approximately 41 mg/ml and 20 mg/ml, respectively. After 30 days, a second dose of pTG7101 plasmid was injected (20 mg in 2 ml, administered in 5 s), both groups showing similar hAAT plasma levels (approximately 6 mg/ml) 2 weeks after injection, suggesting that a plateau was reached in both groups.
Quantitative PCR and RT-PCR assays: intrinsic efficacy of gene expression
The real-time PCR and RT-PCR assays were used for quantification of DNA copies and mRNA transcripts of Long-term therapeutic hAAT in plasma by naked DNA SF Aliño et al both the hAAT gene and the mouse a 1 -antitrypsin (MUSaat) gene from livers of transfected mice. The precise amount of RNA (based on optical density) and its quality (lack of degradation) were normalized with respect to an endogenous control gene (18S rRNA). The method used for obtaining quantitative data of gene amount and relative gene expression was the comparative Ct method as described by the manufacturer (PE-ABI PRISM 7700 Sequence Detection System; User Bulletin #2). The Ct was measured in PCR cycles at which the reporter fluorescent emission increases beyond a threshold level based on the background. In Table 1 we show the normalized results as the DCt value representing the Ct difference from reference and specific genes. Since Ct values are inversely correlated to input target mRNA or DNA levels in the sample, the derived 2 ÀDCt parameter has been proposed as an easy variable directly relating the increased values of 2
ÀDCt with increased amounts of PCR product. In addition, the measure of the intrinsic efficacy (iE) of gene expression (amount of RNA/DNA) can be calculated as the ratio of 2 ÀDCt parameters derived from RT-PCR and PCR analysis. The results show the intrinsic efficacy of mouse AAT gene (iE mAAT ) to be similar in the different experiments, although the intrinsic efficacy of human AAT gene (iE hAAT ) was very dependent upon the gene construct employed for transfection. In all cases, the highest iE was observed with the genomic pTG7101 plasmid, whereas those plasmids based on cDNA such as pMOLK1, pMOLK2 and pAK1 showed 2-, 5-and 20-fold lower efficacies, respectively. In addition, the respective minigenes (K1, K2 and AT1) showed the lowest values. Likewise, the relative amount of human RNA and DNA with respect to mouse and the relative intrinsic efficacy of human versus mouse AAT gene have been calculated in each animal. The results show iE of genomic hAAT gene (pTG7101 plasmid) to achieve 50-76% of the iE of the mouse AAT gene. The relative iE of pMOLK1 plasmid was 40%, whereas all other gene constructs showed iE values of 2-15% with respect to mouse gene. Long-term therapeutic hAAT in plasma by naked DNA SF Aliño et al
Immunostaining of hAAT in mouse liver
Transgenic immunoreactivity ( Figure 6 ) was seen throughout the hepatic lobule, and the stained cells were mainly hepatocytes, which were identifiable by their polygonal shape and rounded nuclei. The stained cells seemed to be most prevalent around the hepatic vein and other distant areas. The exact number of transfected hepatocytes is difficult to determine, since only a low number (approximately 10%) of cells exhibit intense staining, while many show weak brown staining, the specificity of which remains to be determined.
Discussion
We have previously observed 19, 20 that long-term expression and stable plasma levels of hAAT can be achieved by intravenous injection of a plasmid containing the human genomic gene controlled by the natural promoter, although the efficacy was four orders of magnitude lower than that required to mediate a therapeutic effect. As there are two main components in nonviral vectors, the carrier and the gene construct, it remains to be determined how each component influences the final efficacy of gene transfer and the optimal characteristics of the gene construct. 21, 22 In this last respect, experiments were designed to study the in vivo gene transfer efficacy of different gene constructs measuring the protein level in plasma after hydrodynamic transfection, and the iE of the specific gene as the amount of mRNA per gene unit. In all cases using CMV promoter and cDNA gene construct, the hAAT protein levels dropped approximately two orders of magnitude from day 1 to day 30. This biphasic process is similar to the kinetics observed by other authors 17 using gene constructs driven by CMV promoter. However, the experiments employing a gene construct based on genomic DNA driven by the natural promoter showed that the hAAT protein levels in plasma progressively increased to reach therapeutic levels on day 10, and then remained stable for at least 20 days.
The above experiments suggest that pTG7101 plasmid can mediate therapeutic and stable plasma levels of hAAT in mouse plasma. To confirm this observation, we performed additional dose-response experiments. The results support our early suggestions that genomic DNA offers advantages to mediate in vivo hAAT gene transfer, 6, 8, 19, 23 and that the final efficacy is limited by the DNA carrier. 21 , 22 Now we demonstrate that naked nonviral DNA containing genomic hAAT can mediate long-term therapeutic levels of hAAT protein in mouse plasma. In addition, we observe that cDNA and genomic hAAT gene constructs exhibit different biphasic kinetics, in agreement with recent observations employing adenovirus vectors 10 or plasmids. 18, 20 Since in each case different promoters were employed, we suggest that the kinetics observed with the pTG7101 plasmid are mainly Long-term therapeutic hAAT in plasma by naked DNA SF Aliño et al due to the use of a gene in genomic configuration, which could offer advantages for gene expression and stability. We do not know the exact mechanism by which this may occur, although the relative strength of the hAAT promoter/enhancer or introns could play a role in maintaining the stable expression phenotype mainly when longer regions up-and downstream of gene are enclosed in pTG7101 plasmid. In this respect it has been suggested 24 that matrix attachment region and intronic sequences together may interact with the nuclear matrix resulting in persistent gene expression. Also, recently 25 it has been described that large concatemers of linear DNA are more likely to be in transcriptional conformation than in circular plasmid form, but it remains to be established whether concatemer formation itself or other factors are responsible for maintaining transcriptional activity. Although the mechanism of persistent gene expression from some of the plasmid DNA is currently unknown, differential gene-plasmid distribution into the nucleus could be involved, since hAAT forms part of a serpin gene family, and the sequence homology of genomic hAAT could offer major affinity for this mouse genome region where the exogenous gene could afford benefits for stability and transcription factors. This interpretation is supported by the fact that (a) the mechanisms that regulate gene activity and chromatin structure seem to be intimately linked; [26] [27] [28] (b) expression of exogenous genes is dependent upon their nuclear localization; 29, 30 and (c) the hAAT gene is expressed in a stable cell-specific manner when the transgene is in the normal chromosomal context. 31 Since no previous dose-response studies of hAAT gene transfer have been conducted with the ability to be analyzed, we are unable to compare our parameters of potency (EC 50 ) and efficacy (E max ). However, we estimate that the efficiency of gene delivery by the hydrodynamic injection of nonviral DNA is not far from that achieved by employing viral vectors. Thus, therapeutic plasma levels of hAAT protein in plasma (approximately 1 mg/ ml) can be achieved 2 weeks after transfection, with 6 Â 10 11 plasmid-gene units, whereas other authors have described similar therapeutic plasma levels of hAAT employing 1.1 Â 10 11 adenovirus particles 10 or 3 Â 10 10 recombinant adeno-associated infectious units. 11 This observation suggests that the potency of nonviral versus viral vectors is only one order of magnitude lower.
In addition, our experiments employing multiple doses indicate that the procedure offers the possibility of readministering plasmid DNA for therapeutic purposes. This is an important consideration, since dose escalation is required to treat many chronic diseases in humans. However, human application of the present transfection procedure requires demonstration of its efficacy in animals larger than a mouse. It is difficult to predict the efficacy of the hydrodynamic method in larger animals, but we hope that modified procedures destined to achieve similar hepatic conditions with lesser volumes could offer a successful approach for liver transfection.
Next, we evaluated the iE of hAAT gene in livers of mice transfected with different plasmids. To this effect, iE is a parameter indicating the amount of mRNA per gene unit. In our case, iE of human or mouse AAT gene was calculated by the quantitative RT-PCR/PCR ratio from previously normalized values with 18S rRNA gene. Our results indicate the existence of a hierarchical order of iE h for the different plasmids: pTG71014pMOLK14 pMOLK24K14K24pAK14AK1. This is in agreement with previous data obtained by ELISA. In addition, relative iE of human versus mouse gene (iE h/m ) was calculated as the iE h /iE m ratio. Our results indicate that pTG7101 is an efficient hAAT gene construct, since 4 months after transfection the efficiency of transgenic expression in mouse liver was about 50-80% that normally expressed by the mouse gene.
In order to identify the liver localization of transgenic expression, we performed immunostaining on liver sections from mice previously (4 months) transfected with 20 mg pTG7101 and noninjected controls, using a polyclonal antibody showing specificity for the human AAT protein over the mouse protein. Transgenic immunoreactivity was seen throughout the hepatic lobule, and the stained cells were mainly hepatocytes, which were identifiable by their polygonal shape and rounded nuclei. The stained cells seemed to be most prevalent Long-term therapeutic hAAT in plasma by naked DNA SF Aliño et al around the hepatic vein and other distant areas. Interestingly, other authors also have described a pericentral vein distribution of lacZ gene expression after hydrodynamic transfection, 17 although a periportal vein distribution has been described after portal injection of a recombinant AAV containing the hAAT gene. 11 These results suggest that a retrograde stream in the liver could be involved in the mechanism of gene transfer via tail-vein injection of DNA by the hydrodynamic procedure. On the other hand, the exact number of transfected hepatocytes is difficult to determine, since only a low number (approximately 10%) of cells exhibit intense staining, while many show weak brown staining, the specificity of which remains to be determined. This is in line with reports by others, 16 showing that approximately 40% of the cells in mice liver express the lacZ gene after hydrodynamic gene transfer.
In the present study, we have reported the highest plasma levels to date of hAAT in mouse plasma (3-6 mg/ml) with therapeutic potential, after in vivo transfection with genomic nonviral DNA. The goodness of the gene construct is supported by the high iE of hAAT gene (very close to that of normal mouse gene) and the long-term gene expression, after a single DNA dose. Although the hydrodynamic procedure has serious limitations for application in clinical practice, the important efficacy of nonviral DNA gene constructs observed in the present study opens a new avenue in the future safety applications of human gene therapy.
Materials and methods
Mice
Male C57BL/6 mice (B&K Universal Ltd.) were used for in vivo experiences of hAAT gene transfer. The animals were maintained under standard laboratory conditions and housed 3-4 per cage. The experiments were approved by the Biological Research Ethics Committee of the Faculty of Medicine of the University of Valencia (Spain).
Reagents
Goat anti-hAAT antibodies (nonconjugated and peroxidase conjugated) were obtained from Sigma (SIGMA Chemical Co., Spain), and the immunohistochemical developing system LSAB from DAKO (Denmark). The pTG7101 plasmid (18.6 kb) containing the full length of the human AAT gene was a generous gift from Dr P Meulien and Dr JP Lecocq (Transgène SA, Strasbourg, France). The pTG7101 plasmid contains a 16.5 kb genomic fragment of hAAT gene, cloned in SalI site of Poly III-I plasmid. In addition, it contains 1.8 kb genome sequence upstream promoter, the promoter and full length of human AAT gene and 3.2 kb downstream gene. The plasmid p216 containing an EcoRI hAAT cDNA cloned in NotI site of CMV-Bgal-7ZF was kindly donated by Dr KP Ponder (Washington University, St Louis, MO, USA). The pMOLK1 (4812 bp), pMOLK2 (5110 bp) and pAK1 (4695 bp) plasmids contain the hAAT cDNA driven by CMV, CMV plus an intron or the hAAT promoter (500 bp), respectively. The minimalistic immunogenically defined gene expression (MIDGE) vectors K1 (2126 bp), K2 (2432 bp) and AT (2017 bp) were kindly donated by Dr A Koenig (Mologen, Berlin, Germany), and were prepared by Eco31I enzyme digestion of the corresponding plasmid. The minigenes are not plasmids, but linear fragments with protected hairpin ends. Figure  1 shows the schematic diagrams of gene constructs used in the present work. MIDGE technology and production are patented by Soft Gene (Berlin, Germany) and licensed to Mologen. Plasmid isolation and purification were performed as previously described. 32 
In vivo gene transfer
The C57BL/6 mice (n¼3 per group) were injected into the tail vein with 2.0 ml saline solution containing different amounts of plasmid DNA (from 0 to 320 mg) using a 3-ml latex-free syringe (Beckton Dickinson) and a time rate of 0.4 ml/s. Mice blood samples (200 ml) were taken from the tail vein, using heparinized glass capillaries. After centrifugation, plasma was recovered and a pool was obtained mixing 50 ml/mouse for each group. The pooled plasma samples were inactivated (551C, 45 min), centrifuged (20 000 g, 15 min) and kept at À201C until ELISA assay.
Determination of hAAT in mouse plasma
The assay was performed in 96-well microtitration plates (CoStar), as previously described. 20 In brief, goat antihAAT (0.2 mg/well) and goat anti-hAAT peroxidase conjugate (1.5 mg/well) are used as capture and detecting antibodies, respectively. Capture antibody (2 mg/ml) diluted in adsorption buffer (carbonate 0.05 M, pH 9.6) is distributed (100 ml/well) in the microplate and incubated at 41C overnight. After three washings (PBSTween 20 0.05%, 200 ml/well), wells are incubated for an additional 2 h at 371C with 1% bovine serum albumin (PBS-albumin, 200 ml/well) to block nonspecific binding sites. After washing (five times), 100 ml of hAAT (from 0 to 30 ng/ml) or serial diluted plasma samples are added. After incubation (2 h, 371C), wells are rinsed five times and incubated for an equivalent time period with goat anti-hAAT peroxidase conjugated (15 mg/ml, 100 ml/ well) in PBS-albumin. The enzymatic reaction is induced with o-phenylenediamine (0.4 ng/ml, in citrate-phosphate buffer, pH 5) with 30% H 2 O 2 (1.5 ml/ml). The reaction is stopped 2.5 min later by adding 2 M H 2 SO 4 . The sensitivity of hAAT detection in mouse plasma was 0.2 ng/ml.
Immunohistochemical staining of hAAT in mouse liver
Animals were anesthetized and killed by cervical dislocation. Livers were removed, fixed in 4% paraformaldehyde and embedded in paraffin. Tissue sections (8 mm) were deparaffinized and rehydrated in water. Following a blocking step with 4% bovine serum albumin in PBS (1 h, 371C), the tissue sections were incubated in antibody solution (1:1000 diluted rabbit anti-hAAT) at 371C for 1 h. Detection was carried out using the peroxidase kit LSAB-2. Tissue was counterstained with hematoxylin before dehydration.
Real-time quantitative PCR (qPCR) and RT-PCR (qRT-PCR)
Livers were cut into small pieces, and homogenized with an Ultra-Turrax homogenizer (2 Â 10 s; 9500 rpm). Subsequently, total RNA and DNA were isolated with a commercial RNA/DNA simultaneous isolation kit Long-term therapeutic hAAT in plasma by naked DNA SF Aliño et al (QIAGEN) according to the instructions of the manufacturer, and cDNA preparation was carried out using reverse transcriptase and random hexamers.
For qPCR, 50 ng of isolated genomic DNA was amplified in a final volume of 25 ml with the SYBR Green Universal PCR Master Mix according to the instructions of the manufacturer (Applera). Primers for hAAT and for MUSaat gene quantification were: hAAT-FW: 5 0 -CAT CGTTACAGCCTTTGCAA-3 0 , hAAT-RV: 5 0 -AGCCTT CATGGATCTGAGCCT-3 0 ; MUSaat-FW: 5 0 -GGCCAG GTTCACAGGATACAAA-3 0 , MUSaat-RV: 5 0 -CCTCAT TAGCCTCTGGTCTTTTCA-3 0 . For qRT-PCR, isolated total RNA was further purified with the NucleoSpin RNA II kit (Macherey Nagel, Cat. No. 740 955 50) according to the instructions of the manufacturer. First-strand cDNA was prepared from 1 mg of RNA with random hexamers using the SYBR Green RT-PCR reagents kit (P/N 4310179; Applera) according to the instructions of the manufacturer. RT-PCR (in a final volume of 50 ml) was performed with onetenth of the resulting first-strand cDNA with primers specific for MUSaat (FW: 5 0 -CTCTCGGGCATGCTT GATGT-3 0 ; RV: 5 0 -AATCCATCAGCAGCACCCAG-3 0 ) and hAAT (FW: 5 0 -GAGGGCCTGAATTTCAACCTC-3 0 ; RV: 5 0 -CCAGGAACTTGGTGATGATAA-3 0 ). The hAAT primers were located on both sides of intron 2, allowing differentiation between the amplified product of cDNA and any amplified product derived from plasmidic or genomic DNA.
For both qPCR and qRT-PCR, a primer set for 18S rRNA was used as described by the manufacturer (Applera; Pre-Developed Assay Reagents for Gene Expression Quantification; P/N 4310893E). Experiments were performed in triplicate, and quantitative results were obtained with the ABI-PRISM 7700 Sequence Detection System (Applera).
